| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1575 | 2016 |
| Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label … MA Dimopoulos, P Moreau, A Palumbo, D Joshua, L Pour, R Hájek, ... The Lancet Oncology 17 (1), 27-38, 2016 | 986 | 2016 |
| Daratumumab plus lenalidomide and dexamethasone for untreated myeloma T Facon, S Kumar, T Plesner, RZ Orlowski, P Moreau, N Bahlis, S Basu, ... New England Journal of Medicine 380 (22), 2104-2115, 2019 | 869 | 2019 |
| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 349 | 2019 |
| Time to redefine myeloma G Pratt, S Bowcock, A Chantry, G Cook, G Jackson, M Lai, E Low, ... British Journal of Haematology 171 (1), 1-10, 2015 | 287 | 2015 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 242 | 2019 |
| Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma … G Cook, AJ Ashcroft, G Pratt, R Popat, K Ramasamy, M Kaiser, M Jenner, ... British journal of haematology 190 (2), e83, 2020 | 115 | 2020 |
| Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma S Gooding, N Ansari-Pour, F Towfic, M Ortiz Estévez, PP Chamberlain, ... Blood, The Journal of the American Society of Hematology 137 (2), 232-237, 2021 | 105 | 2021 |
| Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma MA Dimopoulos, AJ Jakubowiak, PL McCarthy, RZ Orlowski, M Attal, ... Blood cancer journal 10 (2), 17, 2020 | 93 | 2020 |
| Serum-free light-chain assay: clinical utility and limitations MV Bhole, R Sadler, K Ramasamy Annals of clinical biochemistry 51 (5), 528-542, 2014 | 92 | 2014 |
| The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study SA Schey, GJ Morgan, K Ramasamy, B Hazel, D Ladon, S Corderoy, ... British journal of haematology 150 (3), 326-333, 2010 | 78 | 2010 |
| Pathophysiology and management of monoclonal gammopathy of renal significance A Jain, R Haynes, J Kothari, A Khera, M Soares, K Ramasamy Blood advances 3 (15), 2409-2423, 2019 | 73 | 2019 |
| Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life E Terpos, J Mikhael, R Hajek, A Chari, S Zweegman, HC Lee, MV Mateos, ... Blood cancer journal 11 (2), 40, 2021 | 68 | 2021 |
| Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and renal impairment: results from a phase II trial M Dimopoulos, K Weisel, NWCJ van de Donk, K Ramasamy, B Gamberi, ... Journal of Clinical Oncology 36 (20), 2035-2043, 2018 | 68 | 2018 |
| Multiple myeloma in the very elderly patient: challenges and solutions J Willan, TA Eyre, F Sharpley, C Watson, AJ King, K Ramasamy Clinical interventions in aging, 423-435, 2016 | 59 | 2016 |
| Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy K Ramasamy, J Hayden, ZY Lim, GJ Mufti, AYL Ho British journal of haematology 137 (4), 374-375, 2007 | 57 | 2007 |
| Pomalidomide therapy for myeloma S Schey, K Ramasamy Expert opinion on investigational drugs 20 (5), 691-700, 2011 | 50 | 2011 |
| Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease S Gooding, SWZ Olechnowicz, EV Morris, AE Armitage, J Arezes, J Frost, ... Nature communications 10 (1), 4533, 2019 | 47 | 2019 |
| Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone K Ramasamy, Z Lim, A Pagliuca, GJ Mufti, S Devereux Haematologica 91 (8_Suppl), ECR44-ECR44, 2006 | 47 | 2006 |
| First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). PG Richardson, AJ Vangsted, K Ramasamy, S Trudel, J Martínez, ... Journal of Clinical Oncology 38 (15_suppl), 8500-8500, 2020 | 46 | 2020 |
